Evidence map›Paper›PMID 35596202›Full record

Observational studyArthritis research & therapy2022

Monitoring of patients with rheumatoid arthritis by indocyanine green (ICG)-enhanced fluorescence optical imaging treated with anti-TNFα therapy.

S Hertrampf, J Klotsche, Q Schefer, A M Glimm, G R Burmester, P Hoff, G Schmittat, T Häupl, S Hermann, M Backhaus and 1 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

S HertrampfDepartment of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
J KlotscheDeutsches Rheumaforschungszentrum (DRFZ) Berlin, Leibniz Research Network, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Q Scheferregenold GmbH, Zöllinplatz 4, Badenweiler, Germany.
A M GlimmDepartment of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
G R BurmesterDepartment of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
P HoffDepartment of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
G SchmittatDepartment of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
T HäuplDepartment of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
S HermannDepartment of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
M BackhausDepartment of Internal Medicine - Rheumatology and Clinical Immunology, Park-Klinik Weißensee, Berlin, Germany.
Sarah OhrndorfDepartment of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany. sarah.ohrndorf@charite.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFluorescence optical imaging (FOI) enables visualisation of inflammation in both hands in rheumatoid arthritis (RA).

objectiveTo investigate the usefulness of FOI in treatment monitoring under anti-TNFα therapy with certolizumab pegol (CZP) in patients with RA in comparison to clinical and laboratory outcome parameters.

methodsCZP-naïve patients with RA were eligible for this open-label study with an observational period of 52 weeks. Disease activity was monitored by the clinical score DAS28, tender/swollen joint count (TJC-28/SJC-28) and laboratory outcomes for systemic inflammation (CRP and ESR). FOI results were analysed in three different phases (P1-3) and PrimaVistaMode (PVM) by the FOI activity score (FOIAS).

resultsTwenty-eight RA patients (median age 52.5 years, 26 females, thirteen with a history of other biologic therapy) were included. DAS28 (CRP) decreased from moderate disease activity at baseline (median 4.6, IQR 1.8) to low disease activity at week (w)52 (median 2.7, IQR 2.1; p < 0.001). Statistically significant decreases could also be demonstrated for SJC-28 and TJC-28. CRP/ESR were reduced numerically from baseline to w52. FOIAS in P1 (early phase) showed a continuous decrease of enhancement during the course of treatment period: from baseline (median 1.5, IQR 9.3) over w6 (median 1.0, IQR 3.0; p = 0.069), w12 (median 0.5, IQR 3.0; p = 0.171), w24 (n = 27, median 0.0, IQR 3.0; p = 0.004), until w52 (n = 18, median 0.0, IQR 2.8; p = 0.091), which could not be presented for FOIAS in P2, P3 and PVM.

conclusionFOI in P1 appears to be a valuable tool for fast and easy monitoring of treatment response to certolizumab in a clinical setting.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidCertolizumab PegolDouble-Blind MethodFemaleHumansIndocyanine GreenInflammationMiddle AgedOptical ImagingTreatment OutcomeAntirheumatic AgentsCertolizumab PegolIndocyanine GreenAnti-TNFα therapyCertolizumabFluorescence optical imagingInflammationRheumatoid arthritis

Identifiers

PMID35596202
PMCPMC9123785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.